Indication

Facial hyperpigmentation

Facial hyperpigmentation is a common dermatologic condition characterized by the localized or patchy darkening of the skin on the face due to excessive melanin synthesis and deposition within the epidermis or dermis. Read more about Facial hyperpigmentation

10 drugs 8 manufacturers

Drugs that treat it

Common Facial hyperpigmentation therapies.

Showing 10–10 of 10 drugs

Sort

TAZAROTENE

ACNE PRODUCTS·PSORIASIS·+5

TARO/SUN PHARMA

Filter & compare in the drug finder →Opens the drug finder with Facial hyperpigmentation preselected.

News & literature

Coming soon

Related codes

Coming soon

About Facial hyperpigmentation.

It predominantly affects the integumentary system of adults—most frequently individuals with darker skin phototypes and women undergoing hormonal fluctuations.

Pathophysiologically driven by melanocyte hyperactivity triggered by ultraviolet radiation, visible light, cutaneous inflammation, or hormonal influences, it manifests clinically as tan, brown, or gray-brown macules and patches across prominent facial regions such as the forehead, cheeks, and perioral areas.

Common clinical presentations encompassed by this term include melasma, solar lentigines, and post-inflammatory hyperpigmentation.

nih.gov
Facial hyperpigmentation is a common dermatologic condition characterized by the localized or patchy darkening of the skin on the face due to excessive melanin synthesis and deposition within the epidermis or dermis It predominantly affects the integumentary system of adults—most frequently individuals with darker skin phototypes and women undergoing hormonal fluctuations
merckmanuals.com
Facial hyperpigmentation is a common dermatologic condition characterized by the localized or patchy darkening of the skin on the face due to excessive melanin synthesis and deposition within the epidermis or dermis Common clinical presentations encompassed by this term include melasma, solar lentigines, and post-inflammatory hyperpigmentation
nih.gov
It predominantly affects the integumentary system of adults—most frequently individuals with darker skin phototypes and women undergoing hormonal fluctuations Pathophysiologically driven by melanocyte hyperactivity triggered by ultraviolet radiation, visible light, cutaneous inflammation, or hormonal influences, it manifests clinically as tan, brown, or gray-brown macules and patches across prominent facial regions such as the forehead, cheeks, and perioral areas
arizonaderm.com
Pathophysiologically driven by melanocyte hyperactivity triggered by ultraviolet radiation, visible light, cutaneous inflammation, or hormonal influences, it manifests clinically as tan, brown, or gray-brown macules and patches across prominent facial regions such as the forehead, cheeks, and perioral areas
asds.net
Pathophysiologically driven by melanocyte hyperactivity triggered by ultraviolet radiation, visible light, cutaneous inflammation, or hormonal influences, it manifests clinically as tan, brown, or gray-brown macules and patches across prominent facial regions such as the forehead, cheeks, and perioral areas
nih.gov
Common clinical presentations encompassed by this term include melasma, solar lentigines, and post-inflammatory hyperpigmentation
aafp.org
Common clinical presentations encompassed by this term include melasma, solar lentigines, and post-inflammatory hyperpigmentation

Personalize your experience

Follow Facial hyperpigmentation and get updates as they land.

Create a free account

Already a member? Sign in

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it